RDY
Dr. Reddy's Laboratories Limited NYSE Listed Apr 11, 2001$13.29
+1.06%
vs $13.15
Mkt Cap $11.1B
52w Low $12.46
26.5% of range
52w High $15.59
50d MA $13.35
200d MA $13.85
P/E (TTM)
0.3x
EV/EBITDA
-0.6x
P/B
0.0x
Debt/Equity
0.1x
ROE
—
P/FCF
0.9x
RSI (14)
38.80
ATR (14)
$0.18
Beta
0.30
50d MA
$13.35
200d MA
$13.85
Avg Volume
2.2M
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
8-2-337, Road No. 3 · Hyderabad 500034 · IN
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 20, 2026 | AMC | 0.16 | 0.16 | +0.0% | 12.94 | -0.3% | +2.6% | +3.2% | -0.2% | +0.7% | -0.5% | — |
| Oct 24, 2025 | AMC | 0.19 | 0.19 | -1.4% | 14.58 | -0.3% | -0.8% | +0.9% | -8.2% | +0.3% | -1.2% | — |
| Jul 23, 2025 | AMC | 0.21 | 0.20 | -6.7% | 14.60 | +1.0% | +0.8% | -0.3% | +0.2% | +0.4% | -4.5% | — |
| May 9, 2025 | AMC | 0.21 | 0.22 | +4.0% | 13.40 | +2.0% | +4.0% | +1.2% | +0.3% | +1.8% | +0.3% | — |
| Nov 5, 2024 | AMC | 0.21 | 0.04 | -80.6% | 14.61 | +4.7% | +4.0% | -0.7% | +0.1% | -0.7% | -1.5% | — |
| Jul 27, 2024 | AMC | 0.19 | 0.20 | +4.0% | — | — | — | — | — | — | — | — |
| May 8, 2024 | AMC | 0.86 | 0.70 | -18.6% | 14.30 | -1.3% | -2.9% | -0.4% | +1.1% | -0.4% | +0.0% | — |
| Jan 31, 2024 | AMC | 0.18 | 0.20 | +13.3% | 14.39 | -0.5% | +0.6% | -0.3% | +0.9% | +0.5% | +0.3% | — |
| Oct 27, 2023 | AMC | 0.17 | 0.21 | +20.3% | 13.01 | -0.3% | -0.5% | +0.6% | +0.5% | -1.5% | -0.5% | — |
| Jul 26, 2023 | AMC | 0.15 | 0.21 | +36.4% | 13.61 | -1.0% | -0.1% | +1.3% | -0.1% | +0.9% | +0.1% | — |
| May 10, 2023 | AMC | 0.12 | 0.14 | +21.6% | 11.71 | -5.2% | -6.5% | -0.5% | +1.5% | -0.3% | -1.0% | — |
| Jan 25, 2023 | AMC | 0.14 | 0.18 | +32.4% | 10.47 | +0.7% | +0.3% | +1.6% | +0.3% | +0.6% | +0.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 5 | HSBC | Upgrade | Hold → Buy | — | $14.75 | $15.34 | +4.0% | +5.3% | +0.1% | +0.5% | +1.7% | +0.3% |
| Nov 6 | Barclays | Maintains | Overweight → Overweight | — | $14.61 | $15.30 | +4.7% | +4.0% | -0.7% | +0.1% | -0.7% | -1.5% |
| Jul 30 | Barclays | Maintains | Overweight → Overweight | — | $16.40 | $16.35 | -0.3% | -1.6% | +0.8% | +1.5% | +0.8% | -2.9% |
| May 8 | Barclays | Maintains | Overweight → Overweight | — | $14.27 | $14.32 | +0.4% | +0.2% | -2.9% | -0.4% | +1.1% | -0.4% |
| Jan 29 | Barclays | Maintains | Overweight → Overweight | — | $13.91 | $14.15 | +1.7% | +0.7% | -0.9% | +3.7% | +0.6% | -0.3% |
| Jun 1 | Barclays | Maintains | Overweight → Overweight | — | $11.04 | $11.22 | +1.6% | +1.1% | +1.6% | -0.5% | +0.6% | +0.5% |
| Oct 31 | Barclays | Maintains | Overweight → Overweight | — | $11.05 | $10.82 | -2.1% | -1.7% | +2.7% | -0.7% | +0.9% | -0.4% |
| Oct 25 | Barclays | Maintains | Overweight → Overweight | — | $10.51 | $10.64 | +1.2% | +1.9% | +0.8% | +1.0% | +1.3% | -1.7% |
| Sep 12 | Barclays | Maintains | Overweight → Overweight | — | $10.69 | $10.78 | +0.8% | +0.9% | -2.2% | +0.3% | -2.3% | -2.1% |
| Jul 25 | Barclays | Maintains | Overweight → Overweight | — | $11.06 | $10.95 | -1.0% | -1.9% | -2.5% | +2.8% | -3.8% | -1.6% |
| May 24 | Barclays | Maintains | Overweight → Overweight | — | $11.01 | $11.23 | +2.0% | +2.6% | -1.9% | -0.4% | +1.9% | -1.7% |
| Nov 1 | Barclays | Maintains | Overweight → Overweight | — | $12.29 | $12.69 | +3.3% | +3.4% | -0.2% | +0.9% | -0.4% | -0.5% |
| Feb 2 | Barclays | Upgrade | Equal Weight → Overweight | — | $11.83 | $12.28 | +3.8% | +3.0% | +2.7% | +1.4% | +3.3% | +0.5% |
| Jan 28 | CLSA | Maintains | Buy → Outperform | — | $8.84 | $8.77 | -0.8% | +0.7% | -0.3% | -0.5% | -1.0% | +0.9% |
| Jan 9 | Citigroup | Upgrade | Sell → Buy | — | $8.18 | $8.19 | +0.1% | +0.9% | -0.5% | +1.3% | +0.7% | -0.7% |
| Nov 4 | BofA Securities | Downgrade | Buy → Neutral | — | $7.97 | $7.94 | -0.4% | -1.4% | +2.3% | +0.2% | +0.1% | -1.1% |
| Sep 4 | Credit Suisse | Upgrade | Underperform → Outperform | — | $7.05 | $7.17 | +1.7% | +4.4% | +1.6% | +1.9% | +0.9% | +0.7% |
| Jun 11 | Barclays | Maintains | Equal Weight → Equal Weight | — | $7.58 | $7.64 | +0.8% | +0.1% | -0.8% | -2.0% | +0.4% | -2.2% |
| May 20 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $7.88 | $7.39 | -6.2% | -6.1% | +2.7% | -0.4% | -0.4% | +1.2% |
| Nov 1 | Jefferies | Maintains | Underperform → Underperform | — | $7.27 | $7.17 | -1.4% | -1.9% | +5.5% | -2.3% | +0.0% | -2.3% |
| Sep 21 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $7.14 | $7.62 | +6.7% | +5.6% | -0.1% | -2.8% | -2.5% | -3.4% |
| Jul 27 | HSBC | Downgrade | Hold → Reduce | — | $8.82 | $8.71 | -1.2% | -0.7% | -0.5% | +0.1% | +1.9% | -0.9% |
| Jul 27 | Jefferies | Downgrade | Hold → Underperform | — | $8.82 | $8.71 | -1.2% | -0.7% | -0.5% | +0.1% | +1.9% | -0.9% |
| Jul 26 | Credit Suisse | Downgrade | Neutral → Underweight | — | $10.42 | $9.80 | -6.0% | -15.4% | -0.7% | -0.5% | +0.1% | +1.9% |
| May 2 | Goldman Sachs | Maintains | Neutral → Neutral | — | $9.12 | $9.02 | -1.1% | -1.5% | -0.4% | -2.9% | -0.5% | -3.0% |
| Feb 10 | CLSA | Upgrade | Underperform → Buy | — | $8.38 | $8.45 | +0.8% | -0.5% | +1.3% | -1.1% | +2.4% | +4.4% |
| Dec 2 | Deutsche Bank | Maintains | Sell → Sell | — | $9.61 | $9.65 | +0.4% | +0.3% | -1.9% | +0.4% | -2.0% | -6.4% |
| Feb 15 | BofA Securities | Downgrade | Buy → Neutral | — | $6.96 | $6.76 | -2.9% | -2.6% | -0.1% | -0.7% | -1.5% | +0.2% |
| Dec 12 | Credit Suisse | Upgrade | Neutral → Outperform | — | $6.88 | $6.90 | +0.3% | -0.4% | -1.2% | -0.7% | +0.3% | -0.4% |
| Jun 28 | Anand Rathi | Upgrade | Hold → Buy | — | $5.69 | $5.65 | -0.7% | -0.7% | +5.1% | +0.0% | +4.2% | -3.7% |
| Feb 7 | Credit Suisse | Downgrade | Buy → Hold | — | $6.77 | $6.66 | -1.6% | -2.4% | -0.9% | +0.0% | -1.2% | +1.2% |
No insider trades available.
No recent filings available.
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 17,852,102 | $251M | Added | Dec 2025 |
| 2 | Robeco Institutional Asset Management B.v. | 17,177,882 | $238M | Added | Mar 2026 |
| 3 | Royal Bank Of Canada | 9,984,082 | $138M | Added | Mar 2026 |
| 4 | Aikya Investment Management Ltd | 7,999,796 | $111M | Added | Mar 2026 |
| 5 | Renaissance Technologies Llc | 7,859,728 | $109M | Reduced | Mar 2026 |
| 6 | Jpmorgan Chase & Co | 4,371,378 | $59M | Reduced | Mar 2026 |
| 7 | Bnp Paribas Financial Markets | 3,183,971 | $44M | Reduced | Mar 2026 |
| 8 | Vanguard Capital Management Llc | 3,100,911 | $43M | New | Mar 2026 |
| 9 | Franklin Resources Inc | 2,856,094 | $40M | New | Mar 2026 |
| 10 | Marshall Wace, Llp | 2,664,306 | $37M | Added | Mar 2026 |
| 11 | Acadian Asset Management Llc | 2,408,761 | $33M | Added | Mar 2026 |
| 12 | Vanguard Portfolio Management Llc | 1,773,738 | $25M | New | Mar 2026 |
| 13 | Ubs Group Ag | 1,552,308 | $21M | Added | Mar 2026 |
| 14 | Northern Trust Corp | 1,089,329 | $15M | — | Mar 2026 |
| 15 | Quantinno Capital Management Lp | 637,094 | $9M | Added | Mar 2026 |
| 16 | Jane Street Group, Llc | 569,353 | $8M | Reduced | Dec 2025 |
| 17 | Quadrant Capital Group Llc | 979,598 | $7M | Added | Mar 2026 |
| 18 | Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main | 80,000 | $6M | — | Sep 2024 |
| 19 | Citadel Advisors Llc | 446,606 | $6M | Added | Mar 2026 |
| 20 | Aqr Capital Management Llc | 445,277 | $6M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$11.09B
Enterprise Value
-$43.02B
P/E (TTM)
0.26x
Forward P/E
0.24x
PEG Ratio
10.58x
P/B
0.03x
P/S
0.03x
P/FCF
0.92x
EV/EBITDA
-0.56x
Shares Out
834.3M
Financials (TTM)
Revenue
$337.10B
Net Income
$42.88B
EBITDA
$77.27B
Free Cash Flow
$12.03B
Op Cash Flow
$46.43B
EPS Basic
$67.85
EPS Diluted
$51.47
EPS Forward
$55.11
Gross Margin
52.7%
Op Margin
14.7%
Net Margin
12.7%
Balance Sheet
Total Assets
$492.99B
Total Liab.
$155.82B
Total Equity
$337.17B
Cash
$57.91B
LT Debt
$3.80B
Book Value/Sh
$404.61
Debt/Equity
0.14x
Current Ratio
1.92
Quick Ratio
1.37
Returns & Growth
ROE
—
ROA
—
ROIC
13.3%
Rev Growth YoY
+16.6%
EPS Growth YoY
+1.6%
Price Returns
2W
+1.0%
1M
-0.1%
3M
-5.2%
6M
-3.0%
12M
-7.4%
Technicals
52W High
$15.59
52W Low
$12.46
50d MA
$13.35
200d MA
$13.85
RSI (14)
38.80
ATR (14)
$0.18
Beta
0.30
Avg Volume
2.2M
Dividends
Div Rate
$7.99
Div Yield
58.3%
Frequency
1
Ex-Div Date
Jul 25, 2025
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 26, 2026 10:17pm
· Source: financialmodelingprep.com